Tag : Monoclonal

Latest News

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

Newsemia
VANCOUVER, British Columbia–(BUSINESS WIRE)– #AbCellera–LY-CoV555, the lead antibody from the AbCellera and Lilly collaboration, has entered into human testing for the potential treatment of COVID-19....
Latest News

Research Report with COVID-19 Forecasts- Electroporation Instruments Market 2020-2024 | Demand for Monoclonal Antibodies to Boost Growth | Technavio

Newsemia
LONDON–(BUSINESS WIRE)– #ElectroporationInstrumentsMarket–The electroporation instruments market is pomised to grow by USD 72.67 bn during 2020-2024, according to Technavio Source link...
Latest News

Avantor launches new Protein A Chromatography Resin – PROchievA – that provides supply chain flexibility and improves downstream purification performance for monoclonal antibodies (mAbs) production

Newsemia
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced...
Gastroenterology

P150 ENHANCING EPITHELIAL BARRIER FUNCTION WITH NOVEL E-CADHERIN ACTIVATING MONOCLONAL ANTIBODIES REDUCES INFLAMMATORY BOWEL DISEASE PROGRESSION IN MOUSE MODELS

Newsemia
Deficits in gastrointestinal (GI) epithelial barrier function play important roles in the pathogenesis of Inflammatory Bowel Disease (IBD). The CDH1 gene encoding E-cadherin, a key...
Gastroenterology

P069 ONTAMALIMAB, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1, PROVIDES SUSTAINED EXPOSURE FOLLOWING LONG-TERM TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Newsemia
Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission...
Pharma / Biotech

Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.

Newsemia
Related Articles Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase...
Pharma / Biotech

Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.

Newsemia
Related Articles Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Crit Rev Oncol Hematol. 2019 Sep 26;144:102812 Authors: Rofi E, Del Re...
Pharma / Biotech

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.

Newsemia
Related Articles Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2019 Nov 04;: Authors:...
Pharma / Biotech

First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety and tolerability of iscalimab, an anti-CD40 monoclonal antibody.

Newsemia
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety and tolerability of iscalimab, an anti-CD40 monoclonal antibody. Am J Transplant. 2019 Oct 24;: Authors: Espié P,...
Pharma / Biotech

Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.

Newsemia
Related Articles Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer. 2019...
Pharma / Biotech

Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.

Newsemia
Related Articles Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Sep 16;:104476 Authors: Santostefano M, Herzyk D,...
Pharma / Biotech

A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics from In Vitro Data.

Newsemia
Related Articles A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics from In Vitro Data. CPT Pharmacometrics Syst Pharmacol. 2019 Aug 29;: Authors:...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy